Red CAR macrophages attacking blue cancer cells

The ‘Dead-End’ Immune Cell That Could Make CAR Macrophage Therapy Renewable

Engineered macrophages struggle to expand and persist as cancer therapies. USC researchers found a way to grow their upstream progenitors on a massive scale by blocking one enzyme. CAR-engineered versions attacked leukemia and solid tumors in mice. A new receptor design even recruited the host’s immune system across mismatch barriers.